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INTRODUCTION
Eosinophils are produced in the bone marrow along with oth-
er white blood cells and circulate at relatively low levels in the 
bloodstream, making up 1-3% of white blood cells. Eosinophils 
also occur outside the bone marrow and blood vessels: in the 
medulla and the junction between the cortex and medulla of 
the thymus and in the lower gastrointestinal tract, ovary, uterus, 
spleen, and lymph nodes. In allergic conditions, they are found 
in the lung, skin, and esophagus. Eosinophils persist in the cir-
culation for 8-12 hours and can survive in tissues for an addition-
al 8-12 days in the absence of stimulation.
1 Eosinophils are dis-
tinguished based on their characteristic morphological features, 
namely bilobed nuclei and cytoplasmic granules of a distinctive 
granular pink,
2 and they are about 12-17 μm in diameter (Fig. 1). 
While no cell surface proteins unique to eosinophils have as yet 
been recognized, they are armed with abundant specific cyto-
plasmic granules with their structural packaging of cationic pro-
teins, the eosinophils’ most characteristic morphologic feature. 
Eosinophil Development, Regulation of Eosinophil-Specific Genes, 
and Role of Eosinophils in the Pathogenesis of Asthma 
Tae Gi Uhm,
† Byung Soo Kim,
† Il Yup Chung* 
Division of Molecular and Life Sciences, College of Science and Technology, Hanyang University, Ansan, Korea
Eosinophil granules are composed mainly of cytotoxic cationic 
proteins and also harbor a multitude of cytokines and chemo-
kines. Eosinophils are terminally differentiated cells that arise 
from hematopoietic CD34
+ stem cells through commitment and 
differentiation and do not appear to multiply after leaving the 
bone marrow. An interplay of several key transcription factors 
dictates eosinophil lineage development and differentiation, 
and an almost identical set of factors activates transcription of 
eosinophil-specific genes encoding the major basic protein 
(MBP), eosinophil-derived neurotoxin (EDN), eosinophil per-
oxidase (EPO), Charcot-Leyden crystal (CLC) protein, CC che-
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Eosinophils arise from hematopoietic CD34
+ stem cells in the bone marrow. They acquire IL-5Rα on their surface at a very early stage during eosin-
ophilopoiesis, and differentiate under the strong influence of interleukin (IL)-5. They then exit to the bloodstream, and enter the lung upon exposure 
to airway inflammatory signals, including eotaxins. In inflamed tissues, eosinophils act as key mediators of terminal effector functions and innate 
immunity and in linking to adaptive immune responses. Transcription factors GATA-1, CCAAT/enhancer-binding protein, and PU.1 play instructive 
roles in eosinophil specification from multipotent stem cells through a network of cooperative and antagonistic interactions. Not surprisingly, the in-
terplay of these transcription factors is instrumental in forming the regulatory circuit of expression of eosinophil-specific genes, encoding eosinophil 
major basic protein and neurotoxin, CC chemokine receptor 3 eotaxin receptor, and IL-5 receptor alpha. Interestingly, a common feature is that the 
critical cis-acting elements for these transcription factors are clustered in exon 1 and intron 1 of these genes rather than their promoters. Elucidation 
of the mechanism of eosinophil development and activation may lead to selective elimination of eosinophils in animals and human subjects. Further-
more, availability of a range of genetically modified mice lacking or overproducing eosinophil-specific genes will facilitate evaluation of the roles of 
eosinophils in the pathogenesis of asthma. This review summarizes eosinophil biology, focusing on development and regulation of eosinophil-spe-
cific genes, with a heavy emphasis on the causative link between eosinophils and pathological development of asthma using genetically modified 
mice as models of asthma. 
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mokine receptor 3 (CCR3), and interleukin-5 receptor alpha 
(IL-5Rα) chain. Eosinophils are multifunctional leukocytes im-
plicated in the pathogenesis of inflammatory responses, nota-
bly including allergic diseases and parasitic helminth infections. 
Much controversy exists as to the role of eosinophils in homeo-
static and diseased conditions. Recent advances have allowed 
selective removal of eosinophils in rodents and asthmatic pa-
tients through genetic manipulation and therapeutic agents. 
With these tools, we are now in a much better position to deter-
mine the role of eosinophils in the pathophysiology of asthma 
and so develop novel therapeutic approaches. 
Eosinophil development 
Recent advances in the biology of cellular development/dif-
ferentiation have highlighted the fact that any cell type can 
seemingly become any other, given the correct combinations of 
transcription factors and environment. Eosinophil develop-
ment appears to faithfully conform to this notion. Eosinophil 
lineage fate is determined by the interplay of a few key transcrip-
tion factors, including CCAAT/enhancer-binding protein (C/
EBP family member), GATA-1 (a zinc finger family member), 
PU.1 (an Ets family member), and friend of GATA (FOG). In par-
ticular, C/EBPα/β and GATA-1, either individually or in concert, 
play a decisive role in eosinophil commitment from multipo-
tent stem cells. C/EBPs are a family of transcription factors that 
contain a highly conserved, basic-leucine zipper domain at the 
C-terminus that is involved in dimerization and DNA binding. 
Six members of this family (α, β, γ, δ, ε, and ζ) have thus far been 
isolated and characterized.
3 Expression of NF-M, the chicken 
homolog of C/EBPβ, fused to the ligand binding domain of es-
trogen receptor induces the up-regulation of an eosinophil-
specific surface marker EOS47 along with the down-regulation 
of a specific marker of a multipotent chicken progenitor cell 
line transformed by the Myb-Ets oncoprotein.
4 Mice with a null 
mutation in C/EBPα fail to generate eosinophils and neutrophils, 
whereas other hematopoietic lineages, including monocytes, 
are not affected.
5 The enforced expression of either C/EBPα or 
C/EBPβ induces eosinophil differentiation of the chicken-trans-
formed cells.
6 A dominant negative C/EBP that antagonizes all 
C/EBP members blocks granulocyte and monocyte develop-
ment from human cord blood CD34
+ progenitors.
7 There is a 
functional redundancy of C/EBPα and C/EBPβ family mem-
bers for granulocyte development/differentiation, although C/
EBPβ-deficient mice do not show any defects in formation of 
myeloid lineage, unlike C/EBPα.
8 Additionally, a dominant neg-
ative C/EBPβ phenotype induces the formation of immature 
eosinophils, indicating that C/EBPβ also promotes eosinophil 
maturation.
6
GATA-1 is a member of the GATA family of transcription fac-
tors that contain two zinc finger motifs. GATA-1 is expressed in 
the hematopoietic system, including by erythroid cells, mega-
karyocytes, eosinophils, and mast cells and in the Sertoli cells 
of the testis.
9 GATA-1 reprograms avian myeloblastic cell lines 
to eosinophils, and its expression level fine tunes development 
of the eosinophil lineage.
10 Human cord blood CD34
+ cells that 
are transduced by GATA-1-expressing retrovirus exclusively give 
rise to eosinophils. The C-terminal zinc finger motif of GATA-1 
is necessary for formation of eosinophils, and GATA-1-deficient 
fetal liver cells lack the ability to form eosinophils.
11 Deletion of 
a high-affinity GATA-binding site in the GATA-1 promoter, 
∆dblGATA, leads to selective loss of the eosinophil lineage, 
whereas development of platelet, mast cells, and red blood cells 
remains little-changed.
12 When granulocyte/macrophage pro-
genitors (GMPs) are isolated from bone marrow cells of trans-
genic GATA-1 reporter-tagged GFP and grown in liquid culture, 
eosinophils are found only in the GFP-positive fraction, along 
with acquisition of surface IL-5Rα.
13 C/EBPβ and GATA-1 syn-
ergistically regulate activity of MBP promoter.
14 The level of 
GATA-1 expression is an important element in establishing the 
eosinophil phenotype, as it activates an eosinophil-specific 
gene at low, and represses it at high, GATA-1 concentrations.
10,15 
Additionally, the timing of expression of these transcription fac-
tors is critical. For instance, when GATA-2 acts on GMPs ex-
pressing C/EBPα, it exclusively induces eosinophil formation, 
whereas it instructs GMPs to form basophils and/or mast cells 
if GMPs are not expressing C/EBPα.
16 GATA-2 has an instructive 
capacity toward eosinophil lineage from human cord blood 
CD34
+ progenitors comparable to that of GATA-1 and efficient-
ly compensates for GATA-1-deficiency in terms of eosinophil 
development in vivo.
11 GATA-2 also complements GATA-1 to 
activate EDN transcription.
17 Nonetheless, the in vivo role of 
GATA-2 in eosinophil development remains to be determined, 
as GATA-2-deficient mice display a general reduction in hema-
topoiesis, and a complete lack of mast cells.
18
Given that the two transcription factors GATA-1 and C/EBP 
serve as the master regulators of eosinophil development, it is 
proper to mention how GATA-1 and C/EBP might  induce eo-
sinophil formation in CD34
+ cells. Two models have been pro-
posed.
19 In the first, stochastic expression of either GATA-1 or 
C/EBPα in a common progenitor induces expression of the 
other, resulting in co-expression of both factors and ultimately 
eosinophil formation. In the second model, each of the factors 
Fig. 1.  Eosinophils. (A) Peripheral blood eosinophils purified by negative selec-
tion. (B) and (C) Cord blood-derived eosinophils. Cord blood CD34
+ cells were 
cultured for 18 days with a cytokine cocktail. Cultured cells were stained with 
Diff Quick (B) or probed with FITC-conjugated anti-MBP antibody (C). DAPI and 
MBP stains are shown in blue and green, respectively.
A B CUhm et al.
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acts on a distinct type of CD34
+ cell, leading to production of 
eosinophil lineage. These authors favor the second model, as 
several distinct subpopulations of CD34
+ cells exist, and Myb-
Ets-transformed multipotent progenitor cells can readily be 
converted to any cell type depending on the combination of 
transcription factors, including C/EBP, GATA-1, PU.1, and FOG 
(see below), to which they are exposed. 
Other players also act in concert with C/EBP and GATA-1 in 
the process of eosinophil commitment. PU.1 is a transcription 
factor with a winged helix-turn-helix DNA binding domain that 
is a member of the Ets transcription family and is expressed in 
hematopoietic cells, including myeloid cells.
20 Conditional acti-
vation of PU.1 in Myb-Ets-transformed multipotent progenitor 
cells induces the formation of cells with properties of immature 
eosinophils after short-term culture.
21 The mechanism by which 
PU.1 induces eosinophil commitment in transformed cells in-
volves downregulation of GATA-1 expression,
22 agreeing with 
the observation that an intermediate GATA-1 level is required 
for eosinophil commitment.
10,15 When PU.1 is co-expressed 
with C/EBPε32 and GATA-1, however, it transactivates the MBP 
promoter.
22 Hence, PU.1 differentially exerts its function de-
pending on the context of available transcription factors. FOG 
contains nine zinc fingers, at least two of which are capable of 
binding to the N-terminal finger motif of GATA-1.
23 Expression 
of FOG in eosinophils leads to a loss of eosinophil markers and 
the acquisition of a multipotent lineage, and constitutive ex-
pression of FOG in multipotent progenitors inhibits activation 
of MBP gene transcription by GATA-1,
14 C/EBPβ,
24 or a combi-
nation of GATA-1, C/EBPε32, and PU.1.
22 Thus, FOG acts as a 
repressor of the eosinophil lineage. These results highlight the 
importance of both cooperative and antagonistic interactions 
of multiple transcription factors for eosinophil-lineage com-
mitment from multipotent hematopoietic progenitors. 
The involvement of two additional transcription factors in eo-
sinophil development has been documented. IFN consensus 
sequence binding protein (Icsbp) is an IFN-γ-induced transcrip-
tion factor that regulates IFN-responsive genes.
25 Icsbp-deficient 
mice have reduced eosinophil developmental potential and 
eosinophil progenitors. Eosinophil progenitors from icsbp-de-
ficient mice show reduced expression of GATA-1 and are un-
able to respond to IL-5 in terms of eosinophil colony forma-
tion.
26 Therefore, Icsbp appears to play a critical role in the de-
velopment of the eosinophil lineage, although little known 
about the underlying molecular mechanism. Id proteins are 
basic helix-loop-helix transcription factors that lack a basic 
DNA binding domain.
27 Constitutive expression of Id1 inhibits 
eosinophil development, whereas Id2 accelerates the final mat-
uration of eosinophils. The effects of Id factors do not seem to 
be restricted to eosinophils, however, because they also pro-
mote neutrophil development and maturation.
28 Notch is an 
evolutionarily conserved transmembrane protein that regu-
lates a broad spectrum of cell-fate decisions and differentia-
tion.
29 Notch signaling promotes eosinophil maturation
30 as well 
as affecting eosinophil functionality.
31,32 However, whether Notch 
signaling modulates the transcription factors or unidentified 
pathways key for deciding eosinophil fate or is itself affected by 
these factors remains to be determined.
Once multipotent progenitor cells commit to becoming eo-
sinophil progenitors, they go through several intermediate stag-
es before becoming fully mature eosinophils that are seen in 
the circulation and tissues. These stages include promyeloblasts, 
promyelocytes, metamyelocytes, band form, and segmented 
form, based on morphological criteria.
33 As readouts in most 
studies of hematopietic development are measured by the for-
mation of fully mature cells, it is difficult to identify the exact 
development/differentiation stage at which a particular tran-
scription factor exerts its function. Most of the aforementioned 
transcription factors positively or negatively act on the commit-
ment stage. These include GATA-1, GATA-2, C/EBPα, C/EBPβ, 
C/EBPε, PU.1, Icsbp, FOG, and Id1, whereas fewer numbers of 
transcription factors are known to specifically act on the late or 
terminal stages (Fig. 2A). For instance, Id2
28 and moderate 
GATA-1 levels
10,15 are required for progression through matura-
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37
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Fig. 2.  Eosinophil development. (A) Transcription factors regulating eosinophil 
commitment and maturation. Eosinophil commitment is dictated largely by two 
transcription factors, CCAAT/enhancer-binding protein (C/EBP) and GATA-1, 
whose levels and functions are fine-tuned by interactions with the other tran-
scription factors PU.1 and friend of GATA (FOG). Icsbp and Id1 individually regu-
late eosinophil formation, although their relationship with C/EBP and GATA-1 
are unknown. Eosinophil maturation is driven by a similar combination of tran-
scription factors but is inhibited by C/EBPe. Notch signaling prevents eosinophil 
maturation by an unknown mechanism. (B) Different pathways of eosinophil 
development in the mouse and human. Human eosinophil progenitors arise di-
rectly from a common myeloid progenitor, whereas mouse eosinophil progeni-
tors arise from a common myeloid progenitor via a granulocyte/macrophage 
progenitor that is bipotent for eosinophils and neutrophils. 
A
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tion, whereas C/EBPε14/27 isoforms, which are highly ex-
pressed on peripheral blood eosinophils
34 and terminally dif-
ferentiated eosinophils,
35 block MBP transcription. Given that a 
wide spectrum of transcription factors is present in mature eo-
sinophils, they may influence late-stage eosinophil differentia-
tion and maturation. These molecules could be novel targets 
for therapeutic approaches to eosinophil-associated inflamma-
tion.
Despite sharing many features, such as transcription factors 
for eosinophil commitment and maturation, there are subtle 
differences in the lineage pathway through which eosinophils 
are generated in mice and humans (Fig. 2B). In mouse hemato-
poiesis, eosinophil potential exists along with the granulocyte/
monocyte differentiation pathway from hematopoietic stem 
cells, and at least a fraction of granulocyte/macrophage pro-
genitors (GMPs) are bipotent for the eosinophil and the neutro-
phil lineages. Eosinophil progenitors are found within cells ac-
tivating GATA-1, whereas GMPs that do not express GATA-1 
give rise to neutrophils and macrophages. Thus, eosinophil 
progenitors exist as a distinct population downstream of GMP.
13 
The mouse bipotent basophil/mast cell progenitor and the ba-
sophil lineage-committed progenitor are also identified down-
stream of the granulocyte/macrophage progenitor,
36 suggesting 
that the commitment of eosinophil and basophil/mast lineages 
occurs independently after the multipotent progenitor has lost 
the megakaryocyte/erythroid lineage potential. In contrast, in 
human hematopoiesis, GMPs lack eosinophil potential, and 
eosinophil progenitors are instead found in common myeloid 
progenitors (CMPs) that both do and do not express surface IL-
5Rα. Cells expressing IL-5Rα give rise exclusively to eosinophils 
but never basophils or neutrophils.
37 However, as cells possess-
ing both basophil and eosinophil granules have been found in 
leukemia patients,
38 it is possible that a distinct cell type exists 
that has deviated from the known lineage pathway.
Regulation of eosinophil-specific genes 
Analysis of the transcription factors that control eosinophil-
specific genes may offer insights, at the molecular level, into the 
mechanisms behind the commitment of multipotent progeni-
tors into the eosinophil lineage. Relatively small numbers of 
genes are exclusively or predominantly transcribed in eosino-
phil progenitors and fully differentiated eosinophils.
39 These in-
clude genes encoding eosinophil granule proteins (MBP, ECP, 
EDN, EPO, CLC protein) and surface receptors (IL-5Rα and 
CCR3). Not surprisingly, almost the same set of transcription 
factors that dictate eosinophil commitment and differentiation 
are also involved in controlling transcription of eosinophil-spe-
cific genes. These include C/EBP family proteins, GATA factors, 
and PU.1. The regulatory regions of these genes include known 
or putative binding sites for these transcription factors. Interest-
ingly enough, these cis-acting control elements are clustered in 
the sequences flanking their exon 1 and intron 1 rather than the 
promoter (Fig. 3), although the implication of this for transcrip-
tional regulation remains to be determined.
MBP is a granule protein localized in the crystalline core with 
no known enzymatic activity. Transcriptional regulation of the 
human MBP gene is the most thoroughly studied of all eosino-
phil-specific genes
14,22,34,40,41 because MBP is a representative 
marker of eosinophils, and MBP transcript accounts for up to 
8.1% of the total cellular mRNAs of eosinophils.
42 Two different 
CCR3 
59,60,61,62
IL-5Rα
 65,66,67,68,69
MBP 
14,22,34,41
EDN 
17,45,46,47,48,49
ECP
EPO 
53
Proximal promoter regions of genes encoding eosinophil granule proteins  Proximal promoter regions of CCR3 and IL-5Rα genes
A B
Fig. 3.  Regulatory regions of eosinophil-specific genes. Transcription factor binding sites in the MBP (NM002728.4), EDN (NM002934.2), ECP (NM002935.2), EPO 
(NM000502.4), CCR3 (NM001837.3), and IL-5α genes (NM000564.3). Functional binding sites are indicated by dark figures, and putative binding sites that have not 
been confirmed as functional are indicated by light figures. Numbering is relative to the transcriptional start site of each gene.Uhm et al.
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transcripts arise from differential splicing of alternative MBP 
transcripts from promoters P1 and P2, respectively, located 32 
kb apart in the genomic DNA. The P2 promoter is predomi-
nantly responsible for MBP expression in eosinophil lineage 
cells.
40 The P2 promoter of the MBP gene contains a functional 
GATA site and a C/EBP site (Fig. 3A). Binding of GATA-1 or C/
EBPα/β to its respective binding site transactivates the MBP P2 
promoter.
41 A subsequent study by the same group showed that 
GATA-1 and C/EBPβ interact physically to synergistically trans-
activate the MBP P2 promoter. Furthermore, FOG acts as a neg-
ative cofactor for GATA-1-, but not C/EBPβ-, mediated transac-
tivation.
14 The P2 promoter is activated by GATA-1 alone but is 
synergistically transactivated by low levels of PU.1 in the pres-
ence of optimal GATA-1 levels. PU.1 and C/EBPε individually 
activate the P2 promoter.
34 In addition to GATA-1 and C/EBPβ, 
the combination of GATA-1 and PU.1 transactivates the MBP P2 
promoter.
34 By contrast, C/EBPε14, which lacks the transactiva-
tion domain and is expressed at high levels in terminally differ-
entiated eosinophils,
34,35 strongly inhibits the P2 promoter. C/
EBPε27 also represses P2 promoter activity via protein–protein 
interaction through the C/EBP and/or GATA-binding sites, but 
not the PU.1 sites.
34 Thus, the active transcription complex con-
sisting of well-known transcription factors is required for regu-
lation of MBP P2 promoter activity. The complex includes inter-
actions between GATA-1 and C/EBPα, GATA-1 and C/EBPβ, 
GATA-1 and C/EBPε isoforms, GATA-1 and PU.1, PU.1 and C/
EBPε isoforms, and GATA-1 and FOG.
14,22,34,41 These findings es-
tablish a combinatorial cooperation and antagonism through 
protein–protein interactions of the transcription factors that 
control eosinophil development. 
EDN is a cationic granule protein synthesized in eosinophils,
43 
and it has ribonuclease activity that can degrade the RNA ge-
nomes of some viruses. EDN also has an immunomodulatory 
function in terms of regulation of dendritic cell migration
44. As 
seen in Fig. 3, the key regulatory sequence of EDN transcription 
resides in the promoter and intron, which contain GATA, C/
EBP, PU.1, NFAT, and AP-1 sites,
17,45 most of which are function-
al. PU.1,
46 C/EBP isoforms α, β, and ε47, or NFAT binding
48 to their 
respective binding sites in intron 1 of the gene induces transac-
tivation. The promoter region also contains two GATA sites, 
which are 600 bp apart. GATA-1 and GATA-2 bind the two func-
tional GATA sites in the EDN promoter. GATA-2 can replace the 
effect of GATA-1.
17 Elsewhere, HNF4 interacts with Sp1 to stim-
ulate EDN promoter activity.
49
ECP is found in the matrix of the eosinophil-specific granule 
and has more potent anti-helminthic activity but less ribonu-
clease activity than EDN.
50 The ECP gene sequence is highly ho-
mologous to that of EDN, in particular, with 92% identity in the 
upstream 1-kb sequence.
51 Given that the ECP gene shares with 
the EDN gene all cis-acting elements at identical positions (Fig. 
3), almost identical molecular cues appear to govern regulation 
of gene expression. 
EPO is a heme-containing glycoprotein that possesses peroxi-
dase activity. It is located in the matrix of the granule and has a 
sequence that is closely related to neutrophil myeloperoxidase.
52 
A number of positively and negatively cis-acting elements are 
mapped to the proximal promoter of this gene, including tran-
scription factors Egr-1, H4TF-1, CTCF, UBP-1, and GaEII, al-
though it is not known whether these potential binding sites are 
functional for EPO transcription.
53 Additionally, sequence anal-
ysis shows that binding sites for GATA factors, PU.1, and C/EBP 
are present in intron 1 and the promoter (Fig. 3), again suggest-
ing that the transcription factors for eosinophil development 
are actively involved in the transcriptional regulation of the 
EPO gene. 
CCR3 is constitutively expressed at high levels in eosinophils, 
with 16,000–60,000 receptors per cell; it serves as the primary 
chemokine receptor responsible for eosinophil trafficking to 
tissues in diseased and healthy conditions.
54,55 CCR3 is also ex-
pressed on prominent allergic inflammatory cells, including 
Th2 helper
56 and mast cells.
57 The restricted expression of CCR3 
leads to a notion that it plays an integral role in the pathogene-
sis of allergic diseases including asthma, allergic dermatitis, 
and allergic rhinitis. Furthermore, as airway epithelial cells ex-
press functional CCR3, this protein is postulated to play roles 
beyond simple cell trafficking, such as in airway remodeling.
58 
A recent study revealed that CCR3 serves as an identification 
marker, along with IL-5Rα, in eosinophil progenitors at the very 
early stage of human eosinophil development.
37 Hence, analy-
sis of the transcription factors that control CCR3 expression 
may offer insights into the mechanisms behind the commit-
ment of common myeloid progenitors to the eosinophil lin-
eage. The key sequences for CCR3 gene transcription reside in 
exon 1 and intron 1 rather than in the promoter,
59-61 (Fig. 2B). 
Multiple GATA binding sites are present in exon 1 and intron 1. 
Exon 1, in particular, has five GATA sites, each of which has a 
different GATA-1 binding affinity, with one of the five as a posi-
tively acting element and two as negatively acting elements for 
transcription in vitro.
62 C/EBP and PU.1 binding sites are locat-
ed in the promoter and intron 1 regions, respectively, although 
their function remains to be determined. Additionally, AML-1 
and CREB binding motifs are present in exon 1. We recently 
found evidence that protein binding to AML-1 and CREB sites 
contributes to transactivation of the CCR3 gene (our unpub-
lished results), as much as does GATA binding. Therefore, it is 
plausible that these transcription factors participate in eosino-
phil development and maturation. 
IL-5R consists of heterodimer, a unique ligand-binding α 
chain and β chain shared with IL-3 and GM-CSF receptors that 
is linked to the Janus kinase/signal transducer and activator of 
transcription and phosphoinositol-3-kinase.
63 IL-5R mediates 
their differentiation and maturation, survival, chemotaxis, and 
effector functions.
64 Eosinophils, but not basophils or neutro-
phils, possess a high level of IL-5Rα, and IL-5Rα is a key surface Eosinophil Development and Roles in Asthma AAIR 
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molecule in sorting of murine eosinophil progenitors.
13 Al-
though IL-5Rα is expressed as a result of commitment to the 
eosinophilic lineage,
13 human CMPs that express IL-5Rα give 
rise to only eosinophils.
37 Therefore, IL-5Rα is presumably the 
earliest phenotypic marker that eosinophils acquire at the com-
mitment step of the developmental pathway. Given that IL-
5Rα-positive CMPs are derived from the CMPs that lack this 
surface marker, the signals and transcription factors that induce 
IL-5Rα transcription may play an integral role in eosinophil fate 
decision. An early study demonstrated that 34 bp of the proxi-
mal region of the IL-5Rα promoter serves as the binding site for 
a myeloid- and eosinophil-specific transcription factor.
65 These 
turned out to be RFX family transcription factors, although RFX 
family proteins are not expressed in a myeloid- or eosinophil-
specific manner.
66 An AP-1 site, located upstream of the RFX 
binding site, functionally cooperates with a neighboring EOS 
site to mediate IL-5Rα transcription. C-Jun, CREB, and CREM 
bind to the AP-1 site.
67 There is a second promoter, designated 
P2, for the human IL-5Rα gene. Oct2 transactivates murine B 
cells’ IL-5α gene by binding to its promoter.
68 A short sequence 
of 6 bp within the P2 promoter is responsible for the binding of 
an uncharacterized protein and is sufficient for promoter activ-
ity in eosinophilic cells.
69 In C/EBPα-null mice, expression of 
the IL-5Rα gene was greatly reduced.
69 Moreover, sequence 
analysis of exon 1 and intron 1 as well as promoters shows that 
a number of GATA factors, C/EBP, and PU.1 binding sites are 
concentrated in these sequences (Fig. 2B). Nevertheless, the 
important transcription factors GATA-1 and C/EBP, which are 
believed to direct cells toward the eosinophil lineage, have not 
yet been reported as necessary and/or sufficient for transcrip-
tion of the IL-5Rα gene. 
Although the aforementioned transcription factors are pri-
marily responsible for the regulation of eosinophil-specific 
gene expression, their mere presence even in combination is 
not sufficient for induction of gene transcription. Many eosino-
phil-specific genes encoding eosinophil basic proteins, CCR3, 
and IL-5R are induced by modifiers of histone structure such as 
histone acetyltransferase inhibitors,
14,46,53,60,65 and expression of 
many asthma-related inflammatory genes is affected by these 
agents.
70 DNA methyltransferase inhibitors also have a high 
propensity to alter eosinophil-specific gene expression. More-
over, regulation of these gene products by microRNAs has not 
yet been reported. As the relative importance of role of epigen-
etic regulation has increasingly become evident, the study of 
epigenetic regulation of eosinophil-specific genes is vital. Tak-
en together, these findings show that the deciphering of eosino-
phil-specific gene expression will provide both a molecular ba-
sis for eosinophil development and targets for novel therapies 
for the treatment of eosinophil-associated diseases.
Role of eosinophils in asthma
Eosinophils are associated with the pathogenesis of asthma, 
and the presence of eosinophils in the airway lumen and lung 
tissues is often regarded as a defining feature of this disease.
71 
The role of eosinophils in the pathogenesis of asthma is due to 
their ability to mediate terminal effector functions and innate 
immune responses by secreting a wide variety of cationic pro-
teins, lipid mediators, and cytokines/chemokines. Further-
more, eosinophils are capable of bridging innate and adaptive 
immune responses by elaborating T cells, dendritic cells, and 
mast cells. The recent availability of genetically modified mice 
makes possible the elucidation of a causal relationship between 
eosinophil recruitment and the onset or progression of pulmo-
nary pathologies associated with asthma and provides new in-
sight into the role of eosinophils in the pathogenesis of the al-
lergic disease. In these animals, eosinophils are depleted or 
overproduced by manipulating expression of transcription fac-
tors regulating eosinophil development, production of IL-5 and 
eotaxins, and expression of receptors responding to these cyto-
kines, through transgenic systems, gene disruption, and neu-
tralizing antibodies. Thus, much information on the role of eo-
sinophils roles has been accumulated using experimental mod-
els. This section describes the contribution of eosinophils to the 
pathogenesis of allergic disease within the context of asthma.
Eosinophil-deficient mice 
Two strains of mice that lack eosinophils were engineered in 
different genetic backgrounds. Removal of a high-affinity dou-
ble GATA site from the GATA-1 promoter (∆dbl-GATA) in a 
BALB/c background selectively ablates eosinophils.
12 When 
∆dbl-GATA mice are subjected to a standard experimental 
asthma protocol of sensitization and challenge with allergen, 
the absence of eosinophils does not protect the mice from AHR 
development, but are required for airway remodeling.
72 How-
ever, ∆dbl-GATA mice created in a C57BL/6 background show 
decreased allergen-induced AHR, T cell recruitment to the 
lung, and production of Th2 cytokines and chemokines (Table 
1). Furthermore, adoptive transfer of eosinophils or CCL11/eo-
taxin-1 delivery to ∆dbl-GATA BABL/c mice results in recruit-
ment of lung T cells and restoration of airway inflammation.
73 A 
second line of mice devoid of eosinophils, PHIL mice, was cre-
ated in the C57BL/6 background by transgenic expression of 
diphtheria toxin A driven by the EPO promoter.
74 In this line of 
mice, eosinophils are nearly completely deficient in all organs 
in which they occur under homeostatic conditions. Allergen 
challenge of these mice does not induce AHR or pulmonary 
mucus accumulation, suggesting a link between eosinophils 
and allergic pulmonary pathologies. The combined transfer of 
Th2-polarized OVA-specific transgenic T cells and eosinophils 
to PHIL mice, but not transgenic T cells alone, results in accu-
mulation of the effector T cells and airway Th2 responses, sug-
gesting that the primary role of pulmonary eosinophils is to 
elicit localized recruitment of effector T cells.
75 These data sup-
port the central hypothesis that eosinophils are required for the Uhm et al.
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recruitment of T cells to the lung and thus are not only terminal 
effector cells but also important modulators of allergic asthma. 
IL-5- or IL-5Rα-deficient mice 
IL-5 plays a role in the pathogenesis of eosinophilic inflam-
mation and asthma. Airway allergen challenge in asthmatics 
induces expression of IL-5 by T cells,
76 whereas increased levels 
of IL-5 and MBP can be detected in the airway of symptomatic 
asthmatics.
77 IL-5-deficient mice in a C57BL/6 background fail 
to develop AHR and airway eosinophilia upon aeroallergen 
challenge (Table 2), suggesting an essential role for IL-5 in in-
duction of eosinophilia and development of AHR.
78 Indeed, re-
duced lung eosinophils and AHR are observed in mice treated 
with IL-5 antibodies.
79 IL-5-deficient mice also show lesser al-
terations in tissue remodeling events, including peribronchial 
fibrosis and thickness of the peribronchial muscle layer, along 
with a reduction in the production of TGF-β and MBP by eosin-
ophils.
80 In contrast, IL-5-deficient BABL/c mice develop aller-
gen-induced AHR, as wild-type mice do, despite markedly re-
duced blood and lung eosinophilia,
81,82 suggesting dissociation 
of airway eosinophilia from AHR development. On the other 
hand, transgenic mice that constitutively express IL-5 in the 
lung epithelium develop an accumulation of eosinophils and 
pathologic changes including goblet cell hyperplasia, epithelial 
hypertrophy, and AHR even in the absence of antigen chal-
lenge.
83 Genetic IL-5Rα deficiency decreases antigen-induced 
airway eosinophilia and AHR.
84 The confusion involving the ef-
fect of IL-5 on lung functions is also observed in human clinical 
studies. An initial study using humanized anti-IL-5 antibody in 
patients with mild asthma demonstrated >90% lower blood 
and sputum eosinophilia but was not effective in improving 
lung function, as measured by FEV1.
85 A subsequent study 
showed that anti-IL-5 did not reduce the level of MBP in the 
airways, even in the presence of partially inhibited airway eo-
sinophils (approximately 55%).
86 In contrast, anti-IL-5 therapy 
was effective in treatment of a small group of patients with eo-
sinophilic asthma.
87,88 Thus, studies from both human subjects 
and murine models show that IL-5 is responsible for the induc-
tion of pulmonary eosinophilia, but the role of IL-5-induced 
eosinophils in the pathogenesis of asthma remains unan-
swered. Nevertheless, the association/dissociation of airway 
eosinophilia with lung function seen in some mouse strains 
and the differential clinical benefits of anti-IL-5 therapy have 
important implications for the treatment of asthma and testify 
to the complex pathogenesis of the disease. 
Eotaxins (CCL11, CCL24, and CCL26)- and/or CCR3-deficient 
mice
Three eotaxin family proteins, eotaxin-1/CCL11, eotaxin-2/
CCL24, and eotaxin-3/CCL26 have been identified,
89 all of 
which selectively bind to CCR3. Eotaxin-2 and -3 are distantly 
related to eotaxin-1, with ~30% sequence identity and different 
chromosomal locations. Gene disruption studies of eotaxins-1 
and -2 have been published, and both eotaxin-1 and eotaxin-2 
have not yet been characterized as a functional murine homo-
logue of eotaxin-3 (Table 2). Targeted disruption of CCL11/eo-
taxin 1 leads to partially reduced eosinophil counts in the blood 
and airways under baseline conditions without affecting eosin-
ophil hematopoiesis in the bone marrow. Upon exposure to 
aeroallergen, eotaxin-1-deficient mice show ~70% reductions 
in eosinophil numbers in the airway compared with un-sensi-
tized wild-type mice,
90 but they retain substantial levels of pul-
monary eosinophils. The same knock-out mice have a selective 
reduction (approximately 95%) in eosinophil counts in the jeju-
num and thymus, indicating that eotaxin-1 is a fundamental 
regulator of the physiological trafficking of eosinophils in the 
Table 1.  Mice lacking eosinophils and their phenotypes compared with the wild type
Disrupted gene 
(or transgene)
Mouse 
strain Immunization protocol Major phenotypes
∆dbl GATA BALB/c Standard* Fail to develop eosinophilia in airways and bone marrow.
72 
IIDevelop AHR and goblet 
cell metaplasia.
72,73 Reduced airway remodeling
72
Fungus
† Reduced eosinophilia in airways and lung.
99 Reduced goblet cell metaplasia
∆dbl GATA C57BL/6 Standard Reduced recruitment of CD4
+ T cells.
4 Fail to develop lung inflammation and AHR7
3
Injection of eosinophils or eotaxin-1
‡ Restore recruitment of CD4
+ T cells
4 and lung inflammation
73
(PHIL: EPO promoter- 
driven diphtheria  
toxin A)
C57BL/6 Baseline Eosinophils are absent in bone marrow, uterus, small intestine, and thymus
74
Standard Fail to develop airways eosinophilia
2 and Th2 cytokine production in airways.
75 Partial-
ly reduced goblet cell metaplasia
74
Transfer of eosinophils
§ Recruitment of effector T cells in airways
75 (Restore Th2 cytokine production in air-
ways)
*A protocol in which mice are sensitized via a peritoneal injection followed by intranasal administration of ovalbumin. 
†Intranasal challenge with Aspergillus fumigatus. 
‡Eosinophils and/or eotaxin-1 are delivered via intravenous and intranasal routes, respectively. 
§Eosinophils are injected with ovalbumin-specific T cells via the intratracheal and intravenous routes, respectively.
IIPhenotype identical to that of the wild type.Eosinophil Development and Roles in Asthma AAIR 
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body during health.
91 However, eotaxin 1-deficient mice, whose 
eotaxin gene had been replaced with a transgenic Escherichia 
coli β-galactosidase gene, developed lung eosinophilia in re-
sponse to allergen challenge and had no histologic or hemato-
logic abnormalities,
92 contradicting two earlier studies.
90,91 An-
other study suggested that eotaxin 1-deficient mice in a BALB/
c background possessed no defect in the development of aller-
gen-induced AHR and blood eosinophila, with partially re-
duced airway eosinophilia,
82 suggesting that incomplete elimi-
nation of lung eosinophils is not sufficient to abolish AHR. Eo-
taxin-2-deficient mice have normal baseline eosinophil levels 
in the hematopoietic tissues and gastrointestinal tract. Howev-
er, these mice do not develop airway eosinophilia in response 
to IL-13. Additionally, IL-13 induces eotaxin-2, but not eotax-
in-1, expression by macrophages in BALF. These results suggest 
non-redundant roles for these two CCR3 ligands in response to 
inflammatory airway environments.
93 Eotaxin-1/2 double-defi-
cient mice exhibit a profound decrease in eosinophils in BALF 
and peribronchial tissue compared with mice carrying a single 
deletion, comparable to the effect in CCR3-deficient mice.
94 
Additionally, eotaxin-1 and eotaxin-2 contribute to lung pa-
thology differently: eotaxin-1 is important in the development 
and maintenance of peribronchial eosinophilia,
95 whereas eo-
taxin-2 is primarily responsible for IL-13-induced airway ep-
sonophilia.
93 Another type of double knock-out BALB/c mice 
that are deficient in both IL-5 and eotaxin-1 fail to develop al-
lergen-induced AHR and completely lack eosinophils in the 
blood and lungs, whereas either IL-5 or eotaxin-1-deficient 
mice develop AHR, as do wild-type mice, suggesting that com-
plete removal of airway eosinophils is required to impede AHR 
development. Additionally, Th2 cells in these mice produce re-
duced IL-13 levels, a critical regulator of pathologic changes in 
the asthmatic lung, indicating that eosinophils can link to adap-
tive immune responses by modulating CD4
+ T cell functions.
82
Table 2.  Transgenic and gene knockout mice: phenotypes compared with the wild type
Disrupted gene (or transgene) Mouse strain Immunization 
protocol Major phenotypes
IL-5 KO C57BL/6 Standard Fail to develop airway and blood eosinophilia and AHR7
8
Standard Reduced eosinophilia in airways and epithelium,
80 reduced airway remodeling
80
IL-5 KO BALB/c Standard Reduce or fail to develop airway and blood eosinophilia.
81,82 Develop AHR (the same as 
wild type)*.
81,82 Develop normal levels of specific IgE in serum*
81
(IL-5 TG lung-specific) C57BL/6 Baseline Eosinophilia in blood and bone marrow.
8 Slight airway eosinophilia
83
IL-5α KO BALB/c Standard Reduced airway eosinophilia and specific IgE in levels.
84 Fail to develop AHR
84
Eot-1 KO 129SvEv Baseline Reduced blood eosinophilia.
90 Eosinophils are absent in jejunum and thymus
91
Standard Reduced airway eosinophilia
91
Eot-1 KO BALB/c Standard Develop AHR and blood eosinophili*.
82 
Eot-1 promoter-driven β–gal TG ICR Standard Reduced eosinophilia
82
Eot-2 KO 129SvEv Baseline Fail to develop in airway eosinophilia
92
IL-13
† NO change in eosinophils numbers in bone marrow, blood, spleen, and jejunum
93
Standard No change in AHR
93
Eot-2 KO (IL-13 TG lung) ? Baseline Reduced eosinophils in airways but not in peribronchi
94
Eot-1/2 KO 129SvEv Baseline Reduced airway eosinophilia
93
Standard Increased in bone marrow and blood sinophilia.
94 Eosinophils are absent jejunum
94
CCR3 KO BALB/c Baseline Reduced airway eosinophilia,
16,18 Reduced goblet cell metaplasia
99
Standard Increased spleen eosinophilia.
96 Reduced small intestine eosinophilia
96
Epicutaneous  
sensitization
‡
Reduced lung eosinophilia
94 (eosinophils do not enter lung parenchyma). Develop exac-
erbation of AHR
96. Increased mast cells in airways
96
Fungus
§ Fail to develop skin eosinophilia.
97 Develop splenocyte Th2 cytokine production. Fail to 
develop air way and lung eosinophilia and AHR
97
CCR3 KO C57BL/6 Baseline Reduced airway and lung eosinophilia.
99 Reduced goblet cell metaplasia
99
Standard Reduced blood and spleen eosinophilia.
94 Eosinophils are absent in jejunum
94
Eot-1/IL-5 KO BALB/c Standard Fail to develop airway and peribrochial eosinophilia
94
Fail to develop airway and blood eosinophilia and AHR
82
*Phenotype identical to that of the wild type.
†IL-13 administered via the intratracheal route.
‡Ovalbumin on a patch of gauze is introduced three times into the skin. 
§Intranasal challenge with Aspergillus fumigatus.Uhm et al.
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Analysis of CCR3-deficient mice shows that a lack of CCR3 re-
sults in markedly reduced eosinophil recruitment to the lung, 
with the majority of eosinophils trapped in the subendothelial 
space. However, CCR3-deficient mice unexpectedly exhibit 
greater airway responses to methacholine than do wild-type 
mice when subjected to systemic sensitization followed by re-
spiratory antigen challenge, indicating that CCR3 disruption 
confers no protection, but rather exacerbates AHR.
96 However, 
allergen-challenged CCR3-deficient mice fail to develop AHR 
upon epicutaneous sensitization.
97 Therefore, it is not clear 
whether CCR3 is the dominant pathway in chronic models of 
allergic airway inflammation. Moreover, CCR3-deficient mice 
have more mast cells in the airways after antigen challenge,
96 
reflecting a more complex role for CCR3 in the pathological 
events of asthma. In contrast to the conflicting findings from 
CCR3-deficient mice, administration of anti-CCR3 antibody via 
both systemic and local routes abolishes antigen-induced lung 
eosinophilia and AHR.
98 
To summarize the gene-ablation studies, two axes, IL-5/IL-5R 
and eotaxins/CCR3, play dominant roles in allergen-induced 
pulmonary eosinophilia. However, the contribution of eosino-
phils to the pathogenesis of this allergic disease has been con-
troversial, depending on the rodent strain (largely C57BL/6 vs. 
BALB/c mice), experimental protocol (e.g. aerosol versus cuta-
neous routes, chronic cytokine exposure versus allergen chal-
lenges, and severity of antigen challenge), and pathological 
conditions (e.g. the milieu of Th2 cytokines present in the lung). 
Moreover, conflicting effects of eosinophil depletion are ob-
served in human diseases. Nevertheless, the discrepancies in 
the pathological phenotypes reflect the heterogeneous nature 
of asthma in humans and have important implications for se-
lection of therapeutic targets and designing therapeutic agents.
CONCLUSIONS
Understanding of eosinophil development, trafficking, and 
effector function may lead to the development of a core experi-
mental instrument, reduction or elimination of eosinophils in 
asthma model and human subjects. The anti-eosinophil ap-
proaches allow intense testing of the link of eosinophils to the 
lung functions and pathologies of asthmatic lungs, prove useful 
to identify critical pathways involved in the recruitment and ac-
tivation of eosinophils in the asthmatic lung, and draw atten-
tion to the potential of anti-eosinophil-directed therapeutics. 
Despite increasing knowledge in eosinophil’s role by the use of 
eosinophil-deficient mice in models of disease, none of these 
models fully reflects the human disease. Furthermore, these 
models might not be predictive of the role played by the eosin-
ophil in the human disease. This is at least in part due to the fact 
that the causative relationship between eosinophil activities 
and the onset/progression of allergic respiratory pathology is 
affected by a variety of pathologic conditions and inflammato-
ry microenvironments in the lung and system. Further studies 
are needed to clarify role of eosinophils in diverse disease set-
tings and to identify the downstream mechanism, such as co-
operation with resident lung cells. Such analyses will help to es-
tablish pathophysiological paradigms and to uncover the mo-
lecular insight into disease pathogenesis.
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